PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

January 3, 2023

https://www.globenewswire.com/news-release/2023/01/03/2581989/37149/en/PDS-Biotech-Announces-Exclusive-Global-License-Agreement-for-Investigational-IL-12-Tumor-Targeted-Cytokine-from-Merck-KGaA-Darmstadt-Germany.html

PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform

PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at 8:00 AM EST

Read more at globenewswire.com

Related news for (PDSB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.